NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/18/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,005.39 mln
Float133 mln
Earnings Date11/11/2026
EPS
0.78
Decent
P / E
6.42
Undervalued
Piotroski F-Score
5
/ 9
Neutral
1-Year Forecast
5.47
Modest upside
Relative Strength
42
/ 100
Slightly lagging
Debt / Equity
0.01
Debt-free
Business Description
Arbutus Biopharma is a clinical-stage company based in Warminster, Pennsylvania, focused on developing new treatments for chronic Hepatitis B. Its two lead drug candidates work in complementary ways ? one reduces harmful viral proteins in the body, while the other helps the immune system recognize and fight the infection. The company also holds a licensing agreement with Alnylam Pharmaceuticals to use their drug delivery technology in developing its products.
